Non-Antibiotic Selectable Markers for Bacillus Anthracis
Non-Antibiotic Selectable Markers for Bacillus Anthracis
批准号:
7472107
负责人:
JAMES E KIRBY
金额:
$21.25万
依托单位国家:
美国
项目类别:
财政年份:
2008
资助国家:
美国
项目状态:
已结题
起止时间:
2008-04-01 至 2010-03-31
关键词:
Anthrax diseaseAntibiotic ResistanceAntibiotic TherapyAntibioticsBacillus anthracisBacteriaBenignCandidate Disease GeneChromosomesDevelopmentDiseaseElectroporationEventGene ExpressionGenesGeneticGenetic RecombinationGoalsHeavy MetalsHerbicidesInfectious AgentInvestigationLinkMaintenanceMethodsMinorModificationMutagenesisOrganismPathogenesisPlasmidsPredispositionPropertyPublic HealthRangeRateResearchResearch PersonnelResistanceSeriesSuicideSystemTechnologyTherapeuticToxinVirulencebacterial geneticsbacteriocinbasedesiregene functiongenetic manipulationimprovedinnovationkillingspathogenpressuretoolvector
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): Bacillus anthracis produces highly lethal disease. Unfortunately, antibiotic treatment options remain few, and therapy must be continued for extended periods. These observations highlight the importance of preserving susceptibility to current antibiotic therapies. However, the very technologies that enable genetic manipulation of B. anthracis for scientific study of its virulence properties rely on introduction of antibiotic resistance. This is in the form of antibiotic resistance markers that permit selection of desired recombination events and maintenance of plasmids. Therefore, our current methods of scientific inquiry might limit therapeutic options, endanger researchers, and even provide ready made resistant pathogens for terrorists. The goals of this proposal are two fold: to develop non-antibiotic based selectable marker systems for use in Bacillus anthracis and to develop genetic systems using these markers that will dramatically increase the efficiency of genetic manipulation of this organism. Although being developed for our ongoing investigation of anthrax pathogenesis, these tools will be broadly applicable to a wide range of other bacterial pathogens. Proposed is one specific aim in three parts. In the first, we will define the ability of markers conferring resistance to bacteriocins, heavy metals, chemotherapeutics, and herbicides to function as selectable markers in Bacillus anthracis. Analysis will include study of the markers' activity and stability, as well as an assessment of potential undesirable properties such as induction of cross resistance to antibiotics and effects on virulence. In the second, we will develop new counterselectable markers that serve as a potent tool for deleting genes, since when introduced into the chromosome they enable selection of rare recombination events in which the marker and linked genes have been deleted. As counterselectable markers do not yet exist for B. anthracis and most other gram positive organisms, we propose development of two innovative counterselectable marker systems. These new markers will greatly accelerate discovery, as they will bring new efficiencies to genetic manipulation of B. anthracis. In the third, we will use newly characterized non-antibiotic selectable markers to create a series of vectors that will serve as new tools for bacterial genetic investigation of Bacillus anthracis and other pathogens.
PUBLIC HEALTH RELEVANCE: The goals of this proposal are to develop new tools for analyzing gene function in Bacillus anthracis, the cause of anthrax. The new methods will provide an alternative to the introduction of antibiotic resistance into pathogens, previously needed for this type of research. These new tools will be safer for researchers and the public, accelerate discovery, and find broad use in investigation of a wide range of infectious organisms.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
De Novo Synthesis, and Functional and Structural Characterization of Novel Aminoglycoside Analogues to Bypass Resistance Mechanisms and Optimize Selectivity
-
批准号:10676201
-
项目类别:
-
资助金额:$75.72万
-
财政年份:2020
-
负责人:JAMES E KIRBY
-
依托单位:
Use of De Novo Synthesis Approaches and Structure-guided Design to Optimize Therapeutic Properties of Streptothricin Class Antimicrobials
-
批准号:10469007
-
项目类别:
-
资助金额:$77.22万
-
财政年份:2020
-
负责人:JAMES E KIRBY
-
依托单位:
De Novo Synthesis, and Functional and Structural Characterization of Novel Aminoglycoside Analogues to Bypass Resistance Mechanisms and Optimize Selectivity
-
批准号:10447128
-
项目类别:
-
资助金额:$76.53万
-
财政年份:2020
-
负责人:JAMES E KIRBY
-
依托单位:
Use of De Novo Synthesis Approaches and Structure-guided Design to Optimize Therapeutic Properties of Streptothricin Class Antimicrobials
-
批准号:10269053
-
项目类别:
-
资助金额:$77.75万
-
财政年份:2020
-
负责人:JAMES E KIRBY
-
依托单位:
Use of De Novo Synthesis Approaches and Structure-guided Design to Optimize Therapeutic Properties of Streptothricin Class Antimicrobials
-
批准号:10686110
-
项目类别:
-
资助金额:$76.68万
-
财政年份:2020
-
负责人:JAMES E KIRBY
-
依托单位:
De Novo Synthesis, and Functional and Structural Characterization of Novel Aminoglycoside Analogues to Bypass Resistance Mechanisms and Optimize Selectivity
-
批准号:10242923
-
项目类别:
-
资助金额:$77.26万
-
财政年份:2020
-
负责人:JAMES E KIRBY
-
依托单位:
Fusidic acid derivatization to enhance entry into Gram-negative pathogens
-
批准号:9807473
-
项目类别:
-
资助金额:$26.61万
-
财政年份:2019
-
负责人:JAMES E KIRBY
-
依托单位:
VALIDATION OF A HIGH THROUGHPUT SCREEN FOR KPC PLASMID EVICTION
-
批准号:8891557
-
项目类别:
-
资助金额:$21.75万
-
财政年份:2015
-
负责人:JAMES E KIRBY
-
依托单位:
Plasmid Eviction to Restore Susceptibility in Carbapenem-Resistant Enterobacteriaceae
-
批准号:8954519
-
项目类别:
-
资助金额:$13.05万
-
财政年份:2015
-
负责人:JAMES E KIRBY
-
依托单位:
VALIDATION OF A HIGH THROUGHPUT SCREEN FOR KPC PLASMID EVICTION
-
批准号:8990439
-
项目类别:
-
资助金额:$26.1万
-
财政年份:2015
-
负责人:JAMES E KIRBY
-
依托单位:
Novel Antimicrobials Targeting Bacterial Type IV Secretion Systems
-
批准号:8439168
-
项目类别:
-
资助金额:$39.0万
-
财政年份:2012
-
负责人:JAMES E KIRBY
-
依托单位:
Novel Antimicrobials Targeting Bacterial Type IV Secretion Systems
-
批准号:9123514
-
项目类别:
-
资助金额:$39.15万
-
财政年份:2012
-
负责人:JAMES E KIRBY
-
依托单位:
Novel Antimicrobials Targeting Bacterial Type IV Secretion Systems
-
批准号:8549945
-
项目类别:
-
资助金额:$36.8万
-
财政年份:2012
-
负责人:JAMES E KIRBY
-
依托单位:
Type IV Secretion System Therapeutics
-
批准号:7896197
-
项目类别:
-
资助金额:$21.71万
-
财政年份:2010
-
负责人:JAMES E KIRBY
-
依托单位:
Type IV Secretion System Therapeutics
-
批准号:8041056
-
项目类别:
-
资助金额:$25.84万
-
财政年份:2010
-
负责人:JAMES E KIRBY
-
依托单位:
Non-Antibiotic Selectable Markers for Bacillus Anthracis
-
批准号:7565913
-
项目类别:
-
资助金额:$34.83万
-
财政年份:2008
-
负责人:JAMES E KIRBY
-
依托单位:
The Basis of Anthrax-Induced Vascular Damage
-
批准号:6985044
-
项目类别:
-
资助金额:$21.25万
-
财政年份:2005
-
负责人:JAMES E KIRBY
-
依托单位:
The Basis of Anthrax-Induced Vascular Damage
-
批准号:7140530
-
项目类别:
-
资助金额:$20.75万
-
财政年份:2005
-
负责人:JAMES E KIRBY
-
依托单位:
LEGIONELLA PNEUMOPHILA VIRULENCE FACTORS DEFINED IN VIVO
-
批准号:2442371
-
项目类别:
-
资助金额:$8.26万
-
财政年份:1996
-
负责人:JAMES E KIRBY
-
依托单位:
LEGIONELLA PNEUMOPHILA VIRULENCE FACTORS DEFINED IN VIVO
-
批准号:2886030
-
项目类别:
-
资助金额:$0.55万
-
财政年份:1996
-
负责人:JAMES E KIRBY
-
依托单位:
海外基金